Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The report highlights significant events, including a notable increase in March 2025 sales, with wholesale vehicle sales reaching 268,100 units, representing a year-on-year increase of 66.04% [6] - The company is accelerating its globalization strategy, with plans to enter at least 10 European countries by the end of 2025 and launch new models in the overseas market [6] - The report projects a steady growth in revenue and net profit, with expected revenues of 186.5 billion yuan and net profits of 6.9 billion yuan for 2025 [5][6] Summary by Sections Financial Performance - Main revenue for 2021A was 105.1 billion yuan, increasing to 151.3 billion yuan in 2023A, with projections of 186.5 billion yuan for 2025E [5] - Net profit for 2023A was 11.3 billion yuan, with a forecast of 6.9 billion yuan for 2025E, reflecting a significant drop in growth rate due to market conditions [5] - The gross margin is expected to stabilize around 17% for 2024E and 2025E [5] Sales and Market Strategy - In March 2025, the company achieved a remarkable 119.51% year-on-year increase in new energy vehicle sales, totaling 87,000 units [6] - The company plans to launch several new models, including the deep blue S09 and others, which are expected to enhance its market presence [6] - The report emphasizes the positive impact of new policies and market sentiment from events like the Shanghai Auto Show on future sales growth [6] Global Expansion - The company is focusing on five major projects for global expansion, including establishing a subsidiary in Brazil and launching its brands in the Middle East and Africa [6] - A European brand launch event showcased nine models, indicating a strong commitment to international markets [6] - The report outlines a clear roadmap for achieving a comprehensive business layout across Europe by 2028 [6]

[Table_Reportdate] 2025年04月10日 公 司 简 评 [Table_invest] 买入（维持） 报告原因：重大事项 [证券分析师 Table_Authors] 谢建斌 S0630522020001 xjb@longone.com.cn 联系人 陈芯楠 cxn@longone.com.cn | [数据日期 Table_cominfo] | 2025/04/10 | | --- | --- | | 收盘价 | 12.20 | | 总股本(万股) | 991,409 | | 流通A股/B股(万股) | 826,073/164,1 61 | | 资产负债率(%) | 59.36% | | 市净率(倍) | 1.62 | | 净资产收益率(加权) | 4.95 | | 12个月内最高/最低价 | 18.90/11.32 | [Table_QuotePic] -43% -33% -22% -11% 0% 11% 21% 32% 24-04 24-07 24-10 25-01 长安汽车 沪深300 [相关研究 Table_Report] 《长安汽车（000625）：2月新能源销 量同比提升，智驾平 ...

[Table_Reportdate] 2025年04月10日 [核心Table_NewTitle] CPI转正，PPI仍存结构性矛盾 ——国内观察：2025年3月通胀数据 [证券分析师 Table_Authors] 刘思佳 S0630516080002 liusj@longone.com.cn 证券分析师 胡少华 S0630516090002 hush@longone.com.cn 联系人 李嘉豪 lijiah@longone.com.cn [table_main] 投资要点 宏 观 简 评 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 总 量 研 究 ➢ 事件：2025年4月10日，统计局发布3月通胀数据。3月，CPI当月同比-0.1%，前值-0.7%； 环比-0.4%，前值-0.2%。PPI当月同比-2.5%，前值-2.2%；环比-0.4%，前值-0.4%。 ➢ 核心观点：3月CPI同比虽然仍为负，但CPI环比强于季节性，核心CPI也同比回正，扣除 能源的工业消费品价格表现回升，体现出"两新"政策的效果，不过春节后服务消费走弱 是主要拖累。PPI受 ...

[Table_Reportdate] 2025年04月10日 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 谢建斌 S0630522020001 xjb@longone.com.cn 联系人 商俭 shangjian@longone.com.cn | [数据日期 Table_cominfo] | 2025/04/09 | | --- | --- | | 收盘价 | 15.16 | | 总股本(万股) | 89,069 | | 流通A股/B股(万股) | 89,069/0 | | 资产负债率(%) | 42.39% | | 市净率(倍) | 1.23 | | 净资产收益率(加权) | 14.04 | | 12个月内最高/最低价 | 28.50/14.31 | [Table_QuotePic] -40% -28% -17% -5% 6% 18% 29% 41% 24-04 24-07 24-10 25-01 安徽合力 沪深300 [相关研究 Table_Report] 《安徽合力（600761）：首次海外合 资建厂，全球化布局加速——公司简 评报告》 2025.03.11 《安徽合 ...

[Table_Reportdate] 2025年04月10日 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] [安徽合力（ Table_NewTitle] 600761）：全年销量增速高 于行业，国际化实现新跨越 ——公司简评报告 [table_main] 投资要点 ➢ 风险提示：国际贸易风险；行业竞争风险；技术迭代与全球化进程不及预期风险。 | 盈利预测与估值简表 | | | | | | --- | --- | --- | --- | --- | | 指标 | 2024A | 2025E | 2026E | 2027E | | 营业总收入（百万元） | 17,325.42 | 18,394.61 | 20,254.42 | 21,898.78 | | 同比增长率（%） | 0.99% | 6.17% | 10.11% | 8.12% | | 归母净利润（百万元） | 1,319.63 | 1,383.99 | 1,542.12 | 1,677.84 | | 同比增长率（%） | 0.18% | 4.88% | 11.43% | 8.80% | | EPS 摊薄（元） | 1.4 ...

[Table_Reportdate] 2025年04月10日 [晨会纪要 Table_NewTitle] 20250410 [证券分析师： Table_Authors] 陶圣禹 S0630523100002 tsy@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 王鸿行 S0630522050001 whxing@longone.com.cn [table_main] 重点推荐 财经要闻 | 1.1. PPS，性价比突出的"塑料黄金"——化工系列研究（二十四） | 3 | | --- | --- | | 1.2. 关税政策引发油价波动，关注自主可控石化链标的——原油及聚酯产业链月 | | | 报（2025 4 月） 年 | 4 | | 1.3. 常熟银行（601128）：负债成本管控强化，资产质量管理审慎——公司简评报 | | | 告 | 4 | | 2. 财经新闻 | 5 | | 3. A 股市场评述 | 7 | | 4. ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights strong control over liability costs and prudent asset quality management by the company [1] - The company reported a revenue of 10.909 billion yuan in 2024, representing a year-on-year increase of 10.53%, and a net profit attributable to shareholders of 3.813 billion yuan, up 16.20% year-on-year [2] - As of the end of Q4 2024, the total asset size reached 366.582 billion yuan, with a non-performing loan (NPL) ratio of 0.77%, remaining stable quarter-on-quarter [2][3] - The report indicates a significant increase in the company's efforts to write off non-performing loans, with 1.740 billion yuan written off in the second half of 2024 compared to 968 million yuan in the same period of 2023 [4] Summary by Sections Financial Performance - The company achieved a net interest margin (NIM) of 2.71% for the year, a decrease of 15 basis points year-on-year [2] - The NPL coverage ratio stood at 500.51%, down 27.89 percentage points quarter-on-quarter [2][7] - The projected revenues for 2025, 2026, and 2027 are 11.585 billion yuan, 12.609 billion yuan, and 13.857 billion yuan, respectively, with corresponding net profits of 4.320 billion yuan, 4.782 billion yuan, and 5.268 billion yuan [7][8] Asset Quality - The overall asset quality remains stable, with the NPL ratio at 0.77% as of Q4 2024, and the report notes a marginal improvement in forward-looking indicators, signaling a slowdown in risk [3][4] - The report emphasizes the company's proactive approach in managing asset quality, particularly in the retail loan segment, where the NPL ratio has shown signs of pressure due to macroeconomic conditions [3] Market Position and Strategy - The company is expected to benefit from a broad market space in the small and micro retail sector, leveraging its regional advantages and a combination of technology and support services [7] - The report suggests that the company's high proportion of regular deposits and strong cost control measures will allow it to better navigate the current market environment [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights strong control over liability costs and prudent asset quality management by the company [1] - The company reported a revenue of 10.909 billion yuan in 2024, representing a year-on-year increase of 10.53%, and a net profit attributable to shareholders of 3.813 billion yuan, up 16.20% year-on-year [2] - As of the end of Q4 2024, the total asset size was 366.582 billion yuan, an increase of 9.61% year-on-year, with a non-performing loan (NPL) ratio of 0.77%, remaining stable quarter-on-quarter [2][3] Summary by Relevant Sections Asset Quality - The overall asset quality remains stable, with the NPL ratio at 0.77% as of Q4 2024, unchanged from Q3 2024. Retail and corporate loan NPL ratios were 0.94% and 0.65%, respectively [3] - The report indicates that the company has increased its efforts in non-performing loan recovery and write-offs, with 1.740 billion yuan of non-performing loans written off in the second half of 2024, compared to 0.968 billion yuan in the same period of 2023 [4] Loan and Deposit Growth - Individual loan growth has been weak, consistent with industry trends, while deposit growth remains strong. The company’s deposit absorption continued to grow at a faster pace than the M2 growth rate [6] - The report notes that the company has adjusted its lending strategy to be more cautious in the face of rising retail loan risks, particularly in personal loans and credit cards [6] Interest Margin and Profitability - The net interest margin (NIM) has continued to narrow, with a quarterly NIM of 2.59% in Q4 2024, down from 2.67% in Q3 2024. The company has taken steps to manage deposit costs, including lowering deposit rates [6][7] - Investment income has performed well, driven by a bond bull market, with Q4 investment income and fair value changes amounting to 0.407 billion yuan, significantly higher than 0.149 billion yuan in the same period last year [6] Future Earnings Forecast - The company’s revenue is projected to reach 11.585 billion yuan in 2025, 12.609 billion yuan in 2026, and 13.857 billion yuan in 2027, with corresponding net profits of 4.320 billion yuan, 4.782 billion yuan, and 5.268 billion yuan [8] - The report anticipates a stable performance due to a solid provisioning base and the potential for continued growth in the small and micro retail market [7][8]

[晨会纪要 Table_NewTitle] 20250409 [证券分析师： Table_Authors] 陶圣禹 S0630523100002 tsy@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： [Table_Reportdate] 2025年04月09日 任晓帆S0630522070001 rxf@longone.com.cn 证券分析师： 伍可心 S0630522120001 wkx@longone.com.cn [table_main] 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [Table_Report] ➢ 1.清明消费稳增，旺季将至关注投资机会——清明节消费数据点评 ➢ 2.关注国产替代、内需方向——医药生物行业周报（2025/3/31-2025/4/6） ➢ 3.海尔生物（688139）：业绩逐步企稳，202 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance is gradually stabilizing, and it is expected to return to a good growth trajectory in 2025 [1][5] - The life sciences segment is experiencing continuous innovation and growth, with new product categories accelerating [5] - The medical innovation segment is recovering, with strong growth in hospital automation and public health services [5] - The company has a clear advantage in its niche areas and is actively expanding new business lines, with new orders growing rapidly [5] Financial Summary - Revenue for 2022 was 2,864.04 million, with a year-on-year growth of 34.72%. In 2023, revenue decreased to 2,280.90 million, a decline of 20.36%. It is projected to increase to 2,594.89 million in 2025, reflecting a growth of 13.62% [2] - Net profit attributable to the parent company was 600.79 million in 2022, down 28.90% year-on-year. It is expected to recover to 408.08 million in 2025, with a growth of 11.31% [2] - The gross margin for 2024 is projected to be 47.99%, with a slight decline from previous years [2] - The company’s earnings per share (EPS) for 2025 is expected to be 1.28 yuan, with a price-to-earnings (PE) ratio of 24.95 [2][5] Segment Performance - The life sciences segment generated revenue of 1,094 million in 2024, a year-on-year increase of 6.14%, driven by new product launches [5] - The medical innovation segment's revenue was 1,180 million in 2024, a decrease of 4.91%, but showing signs of recovery in automation and digital services [5] Future Projections - The company is expected to achieve net profits of 4.08 million, 4.83 million, and 5.64 million for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.28, 1.52, and 1.77 yuan [5][6]